RecruitingPhase 1NCT06265688

First In Human Study of CX-2051 in Advanced Solid Tumors

An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors

Sponsor

CytomX Therapeutics

Enrollment

160 participants

Start Date

Apr 2, 2024

Study Type

INTERVENTIONAL

Conditions

Solid Tumor, Adult

Summary

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bevacizumab and a drug called CX-2051 for people with solid tumor, adult. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCX-2051

Investigational drug

DRUGBevacizumab

IV infusion

Locations(8)

Sarah Cannon Research Institute at HealthONE

Denver, Colorado, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Montefiore Medical Center

The Bronx, New York, United States

Carolina BioOncology Institute, PLLC

Huntersville, North Carolina, United States

Sarah Cannon Research Institute, LLC

Nashville, Tennessee, United States

START - Dallas/Fort Worth

Fort Worth, Texas, United States

START San Antonio LLC

San Antonio, Texas, United States

NEXT Virginia

Fairfax, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06265688

Related Trials

Advanced or Recurrent Solid Tumors Treated With SHetA2

NCT049285081 location

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT0691575316 locations

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

NCT068243631 location

Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

NCT049427175 locations